Which medication is considered first-line pharmacotherapy for diabetic gastroparesis?

Which medication is considered first-line pharmacotherapy for diabetic gastroparesis?

• A. Erythromycin
• B. Metoclopramide
• C. Domperidone
• D. Ondansetron

Answer: (B)

In diabetic gastroparesis, the first goal is to improve gastric emptying to relieve symptoms like early fullness, nausea, and vomiting. Metoclopramide fits this role best because it acts as a prokinetic: it blocks dopamine D2 receptors in the gut and enhances acetylcholine release via 5-HT4 receptor stimulation, which together increase coordinated gastric contractions and speed up emptying. This combination has solid clinical evidence and is approved specifically for diabetic gastroparesis, making it the standard initial pharmacotherapy. Be mindful of its limitations: use is generally short-term due to the risk of extrapyramidal effects and tardive dyskinesia with longer treatment. Typical practice uses the lowest effective dose for as short a duration as needed, with careful monitoring for movement disorders, especially in older patients. Erythromycin can mimic prokinetic effects but its benefit often wanes with tachyphylaxis, and it is an antibiotic with broader concerns. Domperidone has prokinetic activity but is not FDA-approved in the United States due to cardiac risks like QT prolongation. Ondansetron helps with nausea and vomiting but doesn’t improve gastric emptying, so it isn’t a first-line treatment for the motility problem itself.

In diabetic gastroparesis, the first goal is to improve gastric emptying to relieve symptoms like early fullness, nausea, and vomiting. Metoclopramide fits this role best because it acts as a prokinetic: it blocks dopamine D2 receptors in the gut and enhances acetylcholine release via 5-HT4 receptor stimulation, which together increase coordinated gastric contractions and speed up emptying. This combination has solid clinical evidence and is approved specifically for diabetic gastroparesis, making it the standard initial pharmacotherapy.

Be mindful of its limitations: use is generally short-term due to the risk of extrapyramidal effects and tardive dyskinesia with longer treatment. Typical practice uses the lowest effective dose for as short a duration as needed, with careful monitoring for movement disorders, especially in older patients.

Erythromycin can mimic prokinetic effects but its benefit often wanes with tachyphylaxis, and it is an antibiotic with broader concerns. Domperidone has prokinetic activity but is not FDA-approved in the United States due to cardiac risks like QT prolongation. Ondansetron helps with nausea and vomiting but doesn’t improve gastric emptying, so it isn’t a first-line treatment for the motility problem itself.